The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
